Literature DB >> 1291087

Blockade of 2,4-dinitrophenol induced ATP sensitive potassium current in guinea pig ventricular myocytes by class I antiarrhythmic drugs.

B Wu1, T Sato, T Kiyosue, M Arita.   

Abstract

OBJECTIVE: The aim was to assess the effects of various antiarrhythmic drugs on 2,4-dinitrophenol (DNP) induced outward current (IDNP), presumably the ATP sensitive K+ current (IK,ATP) of isolated cardiac cells and to discuss mechanisms involved in the hypoglycaemia which occurs in patients on these drugs.
METHODS: The quasi-steady state current-voltage relationship from the isolated guinea pig ventricular cells was measured using whole cell voltage clamp techniques with a ramp pulse programme. The effects of seven different antiarrhythmic drugs on IDNP were examined. Action potentials were elicited at a rate of 0.2 Hz by an intracellular current injection.
RESULTS: DNP (50 mumol.litre-1) increased the quasi-steady state outward current at potentials positive to about -60 mV. This current (IDNP) was completely inhibited by the subsequent application of glibenclamide (1 mumol.litre-1), thereby suggesting that the IDNP is probably IK,ATP. Cibenzoline (10 mumol.litre-1, class Ia), disopyramide (30 mumol.litre-1, class Ia), and procainamide (100 mumol.litre-1, class Ia) significantly inhibited the IDNP by 95.5(SD 11.3)%, 77.8(21.2)%, and 76.4(23.9)% respectively. Flecainide (class 1c) inhibited the IDNP by 66.9(23.9)% at 10 mumol.litre-1 but not at 2 mumol.litre-1. Mexiletine (30 mumol.litre-1, class Ib), pilsicainide (50 mumol.litre-1, class Ic), and E4031 (10 mumol.litre-1, class III) at concentrations as high as approximately fivefold the clinically effective blood levels, did not suppress IDNP. Except for 10 mumol.litre-1 flecainide, all the concentrations listed above which blocked IDNP were within twofold of the clinical blood concentrations documented to be effective for suppression of arrhythmias. Cibenzoline, disopyramide, and procainamide, but not flecainide, belong to class Ia antiarrhythmic drugs. All these class Ia antiarrhythmic drugs "shortened" the action potential duration of guinea pig ventricular cells, an opposite change to that noted for multicellular preparations, eg, guinea pig papillary muscles.
CONCLUSIONS: Class Ia antiarrhythmic drugs (cibenzoline, disopyramide, and procainamide) inhibit IDNP (presumably IK,ATP) in guinea pig ventricular cells within a range of therapeutic concentrations. This inhibitory effect of IK,ATP can probably explain the hypoglycaemia which occurs in some patients receiving these drugs, and the prolongation of the action potential duration alleged to occur in "superfused" papillary muscles.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1291087     DOI: 10.1093/cvr/26.11.1095

Source DB:  PubMed          Journal:  Cardiovasc Res        ISSN: 0008-6363            Impact factor:   10.787


  5 in total

1.  Mexiletine-induced shortening of the action potential duration of ventricular muscles by activation of ATP-sensitive K+ channels.

Authors:  T Sato; S Shigematsu; M Arita
Journal:  Br J Pharmacol       Date:  1995-06       Impact factor: 8.739

2.  Effects of disopyramide and flecainide on the kinetics of inward rectifier potassium channels in rabbit heart muscle.

Authors:  D K Martin; Y Nakaya; K R Wyse; T J Campbell
Journal:  Br J Pharmacol       Date:  1994-03       Impact factor: 8.739

3.  Thrombin receptor and ventricular arrhythmias after acute myocardial infarction.

Authors:  Lilong Tang; Chunyu Deng; Ming Long; Anli Tang; Shulin Wu; Yugang Dong; Louis D Saravolatz; Julius M Gardin
Journal:  Mol Med       Date:  2008 Mar-Apr       Impact factor: 6.354

4.  Effects of cibenzoline, a new class Ia antiarrhythmic drug, on various membrane ionic currents and action potentials of guinea-pig ventricular cells.

Authors:  T Sato; B Wu; T Kiyosue; M Arita
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1994-08       Impact factor: 3.000

5.  Effects of In Vivo Intracellular ATP Modulation on Neocortical Extracellular Potassium Concentration.

Authors:  Azin EbrahimAmini; Bojana Stefanovic; Peter L Carlen
Journal:  Biomedicines       Date:  2022-07-01
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.